Correlation between ESR1 mutation and PD-L1 expression in breast carcinoma: A narrative review.

Abstract excerpt

BACKGROUND: Estrogen receptor alpha (ESR1) mutations emerge in 20-50% of metastatic hormone receptor-positive breast cancers following endocrine therapy and confer constitutive, ligand-independent receptor signalling. Programmed death ligand 1 (PD-L1) serves as a critical immune checkpoint regulator in tumor immune evasion. The relationship between ESR1 mutations and PD-L1 expression represents an important area...

Topics

• Humans
• B7-H1 Antigen
• Breast Neoplasms
• Female
• Mutation
• Estrogen Receptor alpha
• Tumor Microenvironment